UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Machine Learning Identifies Key Proteins in Primary Sclerosing Cholangitis Progression and Links High CCL24 to Cirrhosis

International journal of molecular sciences, 2024-06, Vol.25 (11), p.6042

2024

Volltextzugriff (PDF)

A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage

JHEP reports, 2020-02, Vol.2 (1), p.100064-100064, Article 100064

2020

Volltextzugriff (PDF)

The Role of CCL24 in Primary Sclerosing Cholangitis: Bridging Patient Serum Proteomics to Preclinical Data

Cells (Basel, Switzerland), 2024-01, Vol.13 (3), p.209

2024

Volltextzugriff (PDF)

Ras inhibition induces insulin sensitivity and glucose uptake

PloS one, 2011-06, Vol.6 (6), p.e21712-e21712

2011

Volltextzugriff (PDF)

CCL24 regulates biliary inflammation and fibrosis in primary sclerosing cholangitis

JCI insight, 2023-06, Vol.8 (12)

2023

Volltextzugriff (PDF)

Elevated Levels of Eotaxin-2 in Serum of Fibromyalgia Patients

Pain research & management, 2018-01, Vol.2018 (2018), p.1-4

2018

Volltextzugriff (PDF)

The combined treatment of Copaxone and Salirasib attenuates experimental autoimmune encephalomyelitis (EAE) in mice

Journal of neuroimmunology, 2010-12, Vol.229 (1), p.192-203

2010

Volltextzugriff (PDF)

Clopidogrel attenuates atheroma formation and induces a stable plaque phenotype in apolipoprotein E knockout mice

Microvascular research, 2009-05, Vol.77 (3), p.364-369

2009

Volltextzugriff (PDF)

Targeting CCL24 in Inflammatory and Fibrotic Diseases: Rationale and Results from Three CM-101 Phase 1 Studies

Drug safety, 2024-09, Vol.47 (9), p.869-881

2024

Volltextzugriff (PDF)

LBP-28 - Phase 2a study of CM-101, a CCL24 neutralizing antibody, in patients with non-alcoholic steatohepatitis: a proof-of-concept study

Journal of hepatology, 2023-06, Vol.78, p.S119-S120

2023

Volltextzugriff (PDF)

Phase 2a study of CM-101, a CCL24 neutralizing antibody, in patients with non-alcoholic steatohepatitis: a proof-of-concept study

Journal of hepatology, 2023-06, Vol.78, p.S119-S120

2023

Volltextzugriff (PDF)

Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis

Annals of the rheumatic diseases, 2019-09, Vol.78 (9), p.1260-1268

2019

Volltextzugriff (PDF)

Novel approach combining whole liver single-cell RNA sequencing and spatial gene profiling using Nanostring GEOMX enables identification of specific cell sub-populations and pathways regulated by CCL24

Journal of hepatology, 2022-07, Vol.77, p.S27-S28

2022

Volltextzugriff (PDF)

THU-310 - Targeting CCL24 in primary sclerosing cholangitis with CM101: rationale and study design

Journal of hepatology, 2023-06, Vol.78, p.S985-S986

2023

Volltextzugriff (PDF)

Targeting CCL24 in primary sclerosing cholangitis with CM101: rationale and study design

Journal of hepatology, 2023-06, Vol.78, p.S985-S986

2023

Volltextzugriff (PDF)

OA28 CCL24 serum concentration predicts both vascular and fibrotic complications in systemic sclerosis: rationale for a biological target driven basket trial across disease subsets

Rheumatology (Oxford, England), 2023-04, Vol.62 (Supplement_2)

2023

Volltextzugriff (PDF)

The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+ CD25+ T cells

Atherosclerosis, 2008-04, Vol.197 (2), p.829-839

2008

Volltextzugriff (PDF)

SAT-158 Machine learning-driven identification of serum protein signature for primary sclerosing cholangitis and enhanced liver fibrosis score

Journal of hepatology, 2024-06, Vol.80, p.S295-S295

2024

Volltextzugriff (PDF)

THU-547 Ex-vivo translational assay of hepatic stellate cells using patientderived serum characterizes the anti-fibrotic activity of CM-101

Journal of hepatology, 2024-06, Vol.80, p.S268-S269

2024

Volltextzugriff (PDF)

Hypoxia controls CD4+CD25+ regulatory T‐cell homeostasis via hypoxia‐inducible factor‐1α

European journal of immunology, 2008-09, Vol.38 (9), p.2412-2418

2008

Volltextzugriff (PDF)

Serum CCL24 as a Biomarker of Fibrotic and Vascular Disease Severity in Systemic Sclerosis

Arthritis care & research (2010), 2024-09, Vol.76 (9), p.1269-1277

2024

Volltextzugriff (PDF)

Role of naturally occurring CD4+ CD25+ regulatory T cells in experimental atherosclerosis

Arteriosclerosis, thrombosis, and vascular biology, 2007-04, Vol.27 (4), p.893-900

2007

Volltextzugriff (PDF)

Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes

European heart journal, 2006-11, Vol.27 (21), p.2530-2537

2006

Volltextzugriff (PDF)

CCL24 modulates fibrosis development in primary sclerosing cholangitis: correlation of human serum CCL24 levels with fibrosis markers and data from the Mdr2–/– mouse model

Journal of hepatology, 2020-08, Vol.73, p.S486

2020

Volltextzugriff (PDF)

FRI174 - CCL24 modulates fibrosis development in primary sclerosing cholangitis: correlation of human serum CCL24 levels with fibrosis markers and data from the Mdr2–/– mouse model

Journal of hepatology, 2020-08, Vol.73, p.S486-S486

2020

Volltextzugriff (PDF)

1 – 25 von 105

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(95)
Mit Volltextzugriff
(90)

Publikationsform

Sprache

Englisch
(105)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Machine Learning Identifies Key Proteins in Primary Sclerosing Cholangitis Progression and Links High CCL24 to Cirrhosis

A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage

The Role of CCL24 in Primary Sclerosing Cholangitis: Bridging Patient Serum Proteomics to Preclinical Data

Ras inhibition induces insulin sensitivity and glucose uptake

CCL24 regulates biliary inflammation and fibrosis in primary sclerosing cholangitis

Elevated Levels of Eotaxin-2 in Serum of Fibromyalgia Patients

The combined treatment of Copaxone and Salirasib attenuates experimental autoimmune encephalomyelitis (EAE) in mice

Clopidogrel attenuates atheroma formation and induces a stable plaque phenotype in apolipoprotein E knockout mice

Targeting CCL24 in Inflammatory and Fibrotic Diseases: Rationale and Results from Three CM-101 Phase 1 Studies

LBP-28 - Phase 2a study of CM-101, a CCL24 neutralizing antibody, in patients with non-alcoholic steatohepatitis: a proof-of-concept study

Phase 2a study of CM-101, a CCL24 neutralizing antibody, in patients with non-alcoholic steatohepatitis: a proof-of-concept study

Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis

Novel approach combining whole liver single-cell RNA sequencing and spatial gene profiling using Nanostring GEOMX enables identification of specific cell sub-populations and pathways regulated by CCL24

THU-310 - Targeting CCL24 in primary sclerosing cholangitis with CM101: rationale and study design

Targeting CCL24 in primary sclerosing cholangitis with CM101: rationale and study design

OA28 CCL24 serum concentration predicts both vascular and fibrotic complications in systemic sclerosis: rationale for a biological target driven basket trial across disease subsets

The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+ CD25+ T cells

SAT-158 Machine learning-driven identification of serum protein signature for primary sclerosing cholangitis and enhanced liver fibrosis score

THU-547 Ex-vivo translational assay of hepatic stellate cells using patientderived serum characterizes the anti-fibrotic activity of CM-101

Hypoxia controls CD4+CD25+ regulatory T‐cell homeostasis via hypoxia‐inducible factor‐1α

Serum CCL24 as a Biomarker of Fibrotic and Vascular Disease Severity in Systemic Sclerosis

Role of naturally occurring CD4+ CD25+ regulatory T cells in experimental atherosclerosis

Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes

CCL24 modulates fibrosis development in primary sclerosing cholangitis: correlation of human serum CCL24 levels with fibrosis markers and data from the Mdr2–/– mouse model

FRI174 - CCL24 modulates fibrosis development in primary sclerosing cholangitis: correlation of human serum CCL24 levels with fibrosis markers and data from the Mdr2–/– mouse model

Suchergebnisse filtern